NCT01577550 - Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

October 31, 2013

Study Completion Date

May 31, 2014

Conditions

Psoriasis

Interventions

DRUG

BI 655066 (very high i.v. dose)

Single very high i.v. dose BI 655066

DRUG

Placebo, i.v.

Single i.v. administration of placebo

DRUG

BI 655066 (high s.c. dose)

Single high s.c. dose BI 655066

DRUG

BI 655066 (low i.v. dose)

Single low i.v. dose BI 655066

DRUG

BI 655066 (high medium i.v. dose)

Single high medium i.v. dose BI 655066

DRUG

BI 655066 (very low i.v. dose)

Single very low i.v. dose BI 655066

DRUG

BI 655066 (low s.c. dose)

Single low s.c. dose BI 655066

DRUG

BI 655066 (high i.v. dose)

Single high i.v. dose BI 655066

DRUG

Placebo, s.c.

Single s.c. administration of placebo

DRUG

BI 655066 (low medium i.v. dose)

Single low medium i.v. dose BI 655066

Trial Locations (9)

Unknown

1311.1.0007 Boehringer Ingelheim Investigational Site, Burbank

1311.1.0008 Boehringer Ingelheim Investigational Site, Miami

1311.1.0003 Boehringer Ingelheim Investigational Site, Port Orange

1311.1.0005 Boehringer Ingelheim Investigational Site, Normal

1311.1.0006 Boehringer Ingelheim Investigational Site, Evansville

1311.1.0004 Boehringer Ingelheim Investigational Site, North Dartmouth

1311.1.0002 Boehringer Ingelheim Investigational Site, Pittsburgh

1311.1.4901 Boehringer Ingelheim Investigational Site, Berlin

1311.1.0009 Boehringer Ingelheim Investigational Site, Leeds